4 recruiting. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 4 |
Follow MDD: new trials by email Literature Review of MDD trials Research Report on MDD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inhaled DMT for Major Depressive Disorder N,N-Dimethyltryptamine (15 mg + 60 mg), N,N-Dimethyltryptamine (1 mg + 4 mg) - MDD, Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Universidade Federal do Rio Grande do Norte | 140 | 2026-08-01 | 2026-07-13 |
| Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD LV232 40mg, LV232 60mg, Escitalopram - MDD | Phase 2 | Recruiting | Vigonvita Life Sciences | 400 | 2025-04-03 | 2026-10-20 |
| Psilocybin rTMS for Treatment Resistant Depression Psilocybin, Accelerated intermittent theta burst (aiTBS) rTMS treatment, Low-dose psilocybin - Treatment Resistant Depression, MDD | Phase 2 | Recruiting | University of Texas at Austin | 100 | 2025-01-10 | 2025-11-26 |
| Cancer Related Major Depression Treated With a Single Dose of Psilocybin psilocybin 25 mg sod, psilocybin 1 mg sod - MDD | Phase 2 | Recruiting | Section for Affective Disorders; Northern Stockholm Psychiatry | 100 | 2024-04-19 | 2026-04-13 |
Depressive Disorder, Major (2) · Depression (1) · Depressive Disorder, Treatment-Resistant (1) · Neoplasms (1) · Suicidal Ideation (1) · Suicide (1)
Behavior (2) · Behavioral Symptoms (2) · Depressive Disorder (2) · Mental Disorders (2) · Mood Disorders (2) · Self-Injurious Behavior (1)
Psilocybin (2) · Escitalopram (1) · N,N-Dimethyltryptamine (1) · Population Groups (1) · Superoxide Dismutase (1)
Section for Affective Disorders; Northern Stockholm Psychiatry (1) · Universidade Federal do Rio Grande do Norte (1) · University of Texas at Austin (1) · Vigonvita Life Sciences (1)
Brazil (1) · China (1) · Sweden (1) · United States (1)
Gregory A Fonzo, Ph.D. (1) · Johan Lundberg, MD PhD (1) · Li Huafang (1)
2023 (1)